Adage Capital Partners Amends Travere Therapeutics Stake
Ticker: TVTX · Form: SC 13G/A · Filed: Feb 7, 2024 · CIK: 1438533
| Field | Detail |
|---|---|
| Company | Travere Therapeutics, Inc. (TVTX) |
| Form Type | SC 13G/A |
| Filed Date | Feb 7, 2024 |
| Risk Level | low |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, equity-holdings
TL;DR
**Adage Capital Partners updated their stake in Travere Therapeutics.**
AI Summary
Adage Capital Partners, L.P. filed an amended SC 13G/A on February 7, 2024, indicating a change in their ownership of Travere Therapeutics, Inc. common stock as of December 31, 2023. This filing updates their previous disclosure, showing their current stake in the company. This matters to investors because significant changes in institutional ownership can signal confidence or concern in the company's future prospects, potentially influencing stock price.
Why It Matters
Changes in major institutional holdings can influence investor sentiment and stock price, as large funds often have deep research capabilities.
Risk Assessment
Risk Level: low — This filing is a routine update of institutional ownership and does not inherently signal high risk.
Analyst Insight
Investors should monitor subsequent filings from Adage Capital Partners to understand the full scope of their investment strategy in Travere Therapeutics, and consider this alongside other fundamental analysis.
Key Players & Entities
- Adage Capital Partners, L.P. (company) — the reporting person filing the SC 13G/A
- Travere Therapeutics, Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- $0.0001 (dollar_amount) — par value per share of Travere Therapeutics common stock
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under the Securities Exchange Act of 1934.
Who is the 'Name of Issuer' in this filing?
The 'Name of Issuer' is Travere Therapeutics, Inc., with a CUSIP Number of 89422G107.
Who is the 'Reporting Person' in this filing?
The 'Reporting Person' is Adage Capital Partners, L.P.
What is the 'Date of Event Which Requires Filing of This Statement'?
The 'Date of Event Which Requires Filing of This Statement' is December 31, 2023.
What is the par value of the common stock for Travere Therapeutics, Inc.?
The common stock of Travere Therapeutics, Inc. has a par value of $0.0001 per share.
Filing Stats: 1,975 words · 8 min read · ~7 pages · Grade level 9.7 · Accepted 2024-02-07 07:37:11
Key Financial Figures
- $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securitie
Filing Documents
- p24-0418sc13ga.htm (SC 13G/A) — 97KB
- 0000902664-24-001160.txt ( ) — 99KB
(a)
Item 1(a). NAME OF ISSUER The name of the issuer is Travere Therapeutics, Inc. (the “ Company ”).
(b)
Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES The Company’s principal executive offices are located at 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130.
(a)
Item 2(a). NAME OF PERSON FILING This statement is filed by: (i) Adage Capital Partners, L.P., a Delaware limited partnership (“ ACP ”) with respect to the Common Stock directly owned by it; (ii) Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ ACPGP ”), as general partner of ACP with respect to the Common Stock directly owned by ACP; (iii) Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ ACA ”), as managing member of ACPGP, general partner of ACP, with respect to the Common Stock directly owned by ACP; (iv) Robert Atchinson (“ Mr. Atchinson ”), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the Common Stock directly owned by ACP; and (v) Phillip Gross (“ Mr. Gross ”), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the Common Stock directly owned by ACP. The foregoing persons are hereinafter sometimes collectively referred to as the “ Reporting Persons .” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.
(b)
Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.
(c)
Item 2(c). CITIZENSHIP ACP is a limited partnership organized under the laws of the State of Delaware. ACPGP and ACA are limited liability companies organized under the laws of the State of Delaware. Messrs. Gross and Atchinson are citizens of the United States.
(d)
Item 2(d). TITLE OF CLASS OF SECURITIES Common stock, par value $0.0001 per share (the “ Common Stock ”).
(e)
Item 2(e). CUSIP NUMBER 89422G107 CUSIP No. 89422G107 13G/A Page 8 of 10 Pages Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) Broker or dealer registered under Section 15 of the Act; (b) Bank as defined in Section 3(a)(6) of the Act; (c) Insurance company as defined in Section 3(a)(19) of the Act; (d) Investment company registered under Section 8 of the Investment Company Act of 1940; (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; (j) A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); (k) Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: Not applicable. Item 4. A. Adage Capital Partners, L.P., Adage Capital Partners GP, L.L.C. and Adage Capital Advisors, L.L.C. (a) Amount beneficially owned: 500,000 (b) Percent of class: 0.67%. The percentage set forth in this Schedule 13G/A is calculated based upon, 75,145,831 shares of Common Stock, outstanding as of November 3, 2023, as reported in the Company’s Annual Report on Form 10-Q for the fiscal quarter ended September 30, 2023 filed with the Securities and Exchange Commission on November 7, 2023. (c) (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 500,000 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the di
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. DATE: February 7, 2024 ADAGE CAPITAL PARTNERS, L.P. By: Adage Capital Partners GP, L.L.C., its general partner By: Adage Capital Advisors, L.L.C., its managing member /s/ Robert Atchinson Name: Robert Atchinson Title: Managing Member ADAGE CAPITAL PARTNERS GP, L.L.C. By: Adage Capital Advisors, L.L.C., its managing member /s/ Robert Atchinson Name: Robert Atchinson Title: Managing Member ADAGE CAPITAL ADVISORS, L.L.C. /s/ Robert Atchinson Name: Robert Atchinson Title: Managing Member ROBERT ATCHINSON /s/ Robert Atchinson ROBERT ATCHINSON, individually PHILLIP GROSS /s/ Phillip Gross PHILLIP GROSS, individually